Minaris Regenerative Medicine Appoints Hiroto Bando as New General Manager

Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership.

Hiroto Bando, PhD, who joined Minaris Regenerative Medicine as Deputy General Manager, Regenerative Medicine Business Sector (RMBS), Showa Denko Materials Co., Ltd., in November 2020, will become General Manager, RMBS as well as President and Chief Executive Officer of Minaris Regenerative Medicine, LLC in the United States, effective January 4, 2022. He remains President and Chief Executive Officer of Minaris Regenerative Medicine Co., Ltd., Japan.

In Japan, Takuya Muramoto, PhD, will join Minaris Regenerative Medicine Co., Ltd. in the role of Chief Operating Officer, effective January 1, 2022. He joins the company with more than fifteen years’ experience in the pharmaceutical industry, including five years in cell manufacturing leadership roles at Takeda Pharmaceutical Company Ltd.

Kazuchika Furuishi, PhD, will leave his roles as General Manager, RMBS, Showa Denko Materials Co. Ltd., and President and CEO, Minaris Regenerative Medicine, LLC in the United States, effective January 4, 2022. He will continue to support the business, ensuring a smooth transition, through March 2022. He joined Showa Denko Materials Co., Ltd. for the main purpose of establishing the foundation of a Life Science business strategy through the acquisition of Minaris Regenerative Medicine, LLC (ex “PCT”). He strengthened the business’ competitiveness with global expansion including the acquisition of Minaris Regenerative Medicine GmbH (ex “apceth Biopharma”). He was instrumental in founding the RMBS Yokohama site (current Minaris Regenerative Medicine Co., Ltd.).  

“Congratulations to Hiroto for his appointment as General Manager, RMBS, and CEO of Minaris in the United States and welcome to Takuya to his role as COO of Minaris in Japan. I am pleased to see effective promotion and strengthening for these global and regional roles and have confidence in a successful leadership transition as Minaris Regenerative Medicine continues to deliver on its mission of creating cell therapy miracles together,” said Noriaki Kawata, Corporate Officer, General Manager, Life Science Business Headquarters, Showa Denko Materials Co., Ltd. “We thank Kazuchika for his great leadership to the company over the past years.”